Smart nanoparticles, which can respond to biological cues or be guided by them, are
emerging as a promising drug delivery platform for precise cancer treatment. The field of …

Drug delivery technologies have enabled the development of many pharmaceutical
products that improve patient health by enhancing the delivery of a therapeutic to its target …

Since the introduction of insulin almost a century ago, more than 80 peptide drugs have
reached the market for a wide range of diseases, including diabetes, cancer, osteoporosis …

The oral administration of therapeutic peptides and proteins is favoured from a patient and
commercial point of view. In order to reach the systemic circulation after oral administration …

As one of the most successful therapeutic target families, G protein-coupled receptors
(GPCRs) have experienced a transformation from random ligand screening to knowledge …

Background Glucagon-like peptide-1 receptor agonists (GLP1RA) augment glucose-
dependent insulin release and reduce glucagon secretion and gastric emptying, enabling …

Peptides can offer the versatility needed for a successful oncology drug discovery approach.
Peptide–drug conjugates (PDCs) are an emerging targeted therapeutic that present …

The landmark discoveries of leptin and adiponectin firmly established adipose tissue as a
sophisticated and highly active endocrine organ, opening a new era of investigating adipose …

Proteins and peptides (PPs) have gradually become more attractive therapeutic molecules
than small molecular drugs due to their high selectivity and efficacy, but fewer side effects …

Background Glucagon-like peptide-1 receptor (GLP-1R) agonists are approved for the
treatment of type 2 diabetes and obesity and elicit robust improvements in glycemic control …